Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 20/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.71 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14645722 | 0.93 | HDAC4 (0.86) | HDAC4HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL20838133 | 0.91 | HDAC4 (0.84) | HDAC4HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL20838156 | 0.90 | HDAC4 (0.82) | HDAC4HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL14645579 | 0.90 | HDAC4 (1.00) | HDAC4HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL19688889 | 0.89 | HDAC4 (0.81) | HDAC4HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL21380522 | 0.88 | HDAC4 (0.78) | HDAC4HDAC6HDAC1 | |
| SCHEMBL21175512 | 0.88 | HDAC4 (0.78) | HDAC4HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL14645633 | 0.88 | HDAC4 (1.00) | HDAC4HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL20838089 | 0.87 | HDAC4 (0.79) | HDAC4HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL19688938 | 0.86 | HDAC4 (0.77) | HDAC4HDAC6HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729454-B1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2015-09-16 | — | — | EP | claimed |
| US-9056843-B2 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | claimed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | claimed |
| EP-2729454-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-05-14 | — | — | EP | claimed |
| CN-103764635-A | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG | 2014-04-30 | — | — | CN | claimed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | claimed |
| EP-3291810-B1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-107735088-B | Histone deacetylase inhibitors, compositions and methods of use thereof | CHDI基金会股份有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-20190202795-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190202795-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-07-04 | — | — | US | disclosed |
| US-10053434-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3291810-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| EP-2729454-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| CN-103764635-A | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG | 2014-04-30 | — | — | CN | disclosed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | HDAC4, HDAC5, HDAC6 | HDAC4 1/4885HDAC6 3/4885HDAC1 5/4885 |
| US-20190202795-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885HDAC6 9/4885HDAC1 1/4885 |
| US-10053434-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885HDAC6 9/4885HDAC1 1/4885 |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885HDAC6 9/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.